ALK-Abelló A/S (CPH:ALK.B)
253.00
+2.80 (1.12%)
May 19, 2026, 12:10 PM CET
ALK-Abelló Revenue
ALK-Abelló had revenue of 1.77B DKK in the quarter ending March 31, 2026, with 16.36% growth. This brings the company's revenue in the last twelve months to 6.56B, up 14.94% year-over-year. In the year 2025, ALK-Abelló had annual revenue of 6.31B with 14.00% growth.
Revenue (ttm)
6.56B
Revenue Growth
+14.94%
P/S Ratio
8.45
Revenue / Employee
2.38M
Employees
2,759
Market Cap
55.43B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.31B | 775.00M | 14.00% |
| Dec 31, 2024 | 5.54B | 713.00M | 14.78% |
| Dec 31, 2023 | 4.82B | 313.00M | 6.94% |
| Dec 31, 2022 | 4.51B | 595.00M | 15.19% |
| Dec 31, 2021 | 3.92B | 425.00M | 12.17% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novo Nordisk | 327.80B |
| Coloplast | 28.05B |
| H. Lundbeck | 25.52B |
| Genmab | 25.29B |
| Demant | 22.97B |
| GN Store Nord | 16.60B |
| Zealand Pharma | 9.24B |
| Embla Medical | 6.21B |
ALK-Abelló News
- 13 days ago - ALK-Abelló Quarterly report: Q1 2026 - Filings
- 13 days ago - ALK-Abelló Slides: Q1 2026 - Filings
- 14 days ago - ALK-Abelló Earnings Call Transcript: Q1 2026 - Transcripts
- 14 days ago - ALK-Abelló Quarterly report: Q1 2026 - Filings
- 14 days ago - ALK-Abelló Slides: Q1 2026 - Filings
- 14 days ago - Three-month interim report (Q1) 2026 (unaudited) - GlobeNewsWire
- 15 days ago - ALK upgrades its full-year outlook - GlobeNewsWire
- 4 weeks ago - ALK announces successful outcome of phase 2 trial with its tablet for treatment of peanut allergy demonstrating early onset of efficacy - GlobeNewsWire